huperzine A low dose
Selected indexed studies
- Huperzine a as potential treatment of Alzheimer's disease: an assessment on chemistry, pharmacology, and clinical studies. (Chem Biodivers, 2011) [PMID:21766442]
- Dissolving microneedles for transdermal delivery of huperzine A for the treatment of Alzheimer's disease. (Drug Deliv, 2020) [PMID:32729341]
- The NMDA receptor ion channel: a site for binding of Huperzine A. (J Appl Toxicol, 2001) [PMID:11920920]
_Worker-drafted node — pending editorial review._
Connections
huperzine A low dose protects against
Sources
- Dissolving microneedles for transdermal delivery of huperzine A for the treatment of Alzheimer's disease. (2020) pubmed
- The NMDA receptor ion channel: a site for binding of Huperzine A. (2001) pubmed
- Huperzine A in rat plasma and CSF following intranasal administration. (2007) pubmed
- Poly(lactic-co-glycolic acid) microspheres for the controlled release of huperzine A: in vitro and in vivo studies and the application in the treatment of the impaired memory of mice. (2007) pubmed
- Huperzine a as potential treatment of Alzheimer's disease: an assessment on chemistry, pharmacology, and clinical studies. (2011) pubmed
- A sensitive method for the determination of the novel cholinesterase inhibitor ZT-1 and its active metabolite huperzine A in rat blood using liquid chromatography/tandem mass spectrometry. (2004) pubmed
- Huperzine A inhibits CCL2 production in experimental autoimmune encephalomyelitis mice and in cultured astrocyte. (2013) pubmed
- Acute and chronic studies with the anticholinesterase Huperzine A: effect on central nervous system cholinergic parameters. (1991) pubmed
- Physiological and neurobehavioral effects of cholinesterase inhibition in healthy adults. (2015) pubmed
- Rivastigmine does not alter cocaine-induced subjective effects or self-administration. (2019) pubmed